Ampio Pharmaceuticals, Inc. announced that on March 11, 2019, the Company resubmitted a Special Protocol Assessment with the Food and Drug Administration for a confirmatory Phase III clinical trial of its biological drug, Ampion™, for the treatment of patients afflicted with Osteoarthritis of the Knee.
March 26, 2019
· 4 min read